Impact of risk factors on different interval cancer subtypes in a population-based breast cancer screening programme

Jordi Blanch, Maria Sala, Josefa Ibáñez, Laia Domingo, Belén Fernandez, Arantza Otegi, Teresa Barata, Raquel Zubizarreta, Joana Ferrer, Xavier Castells, Montserrat Rué, Dolores Salas, INCA Study Group, Jordi Blanch, Xavier Castells, Mercè Comas, Laia Domingo, Francesc Macià, Juan Martínez, Ana Rodríguez-Arana, Marta Román, Anabel Romero, Maria Sala, Carmen Alberich, María Casals, Josefa Ibáñez, Amparo Lluch, Inmaculada Martínez, Josefa Miranda, Javier Morales, Dolores Salas, Ana Torrella, Raquel Almazán, Miguel Conde, Montserrat Corujo, Ana Belén Fernández, Joaquín Mosquera, Alicia Sarandeses, Manuel Vázquez, Raquel Zubizarreta, Teresa Barata, Isabel Díez de la Lastra, Juana María Reyes, Arantza Otegi, Garbiñe Sarriugarte, Marisa Baré, Núria Torà, Joana Ferrer, Francesc Castanyer, Gemma Renart, Rafael Marcos-Gragera, Montserrat Puig-Vives, Carles Forné, Montserrat Martínez-Alonso, Albert Roso, Montse Rué, Ester Vilaprinyó, Misericordia Carles, Aleix Gregori, María José Pérez, Roger Pla, Jordi Blanch, Maria Sala, Josefa Ibáñez, Laia Domingo, Belén Fernandez, Arantza Otegi, Teresa Barata, Raquel Zubizarreta, Joana Ferrer, Xavier Castells, Montserrat Rué, Dolores Salas, INCA Study Group, Jordi Blanch, Xavier Castells, Mercè Comas, Laia Domingo, Francesc Macià, Juan Martínez, Ana Rodríguez-Arana, Marta Román, Anabel Romero, Maria Sala, Carmen Alberich, María Casals, Josefa Ibáñez, Amparo Lluch, Inmaculada Martínez, Josefa Miranda, Javier Morales, Dolores Salas, Ana Torrella, Raquel Almazán, Miguel Conde, Montserrat Corujo, Ana Belén Fernández, Joaquín Mosquera, Alicia Sarandeses, Manuel Vázquez, Raquel Zubizarreta, Teresa Barata, Isabel Díez de la Lastra, Juana María Reyes, Arantza Otegi, Garbiñe Sarriugarte, Marisa Baré, Núria Torà, Joana Ferrer, Francesc Castanyer, Gemma Renart, Rafael Marcos-Gragera, Montserrat Puig-Vives, Carles Forné, Montserrat Martínez-Alonso, Albert Roso, Montse Rué, Ester Vilaprinyó, Misericordia Carles, Aleix Gregori, María José Pérez, Roger Pla

Abstract

Background: Interval cancers are primary breast cancers diagnosed in women after a negative screening test and before the next screening invitation. Our aim was to evaluate risk factors for interval cancer and their subtypes and to compare the risk factors identified with those associated with incident screen-detected cancers.

Methods: We analyzed data from 645,764 women participating in the Spanish breast cancer screening program from 2000-2006 and followed-up until 2009. A total of 5,309 screen-detected and 1,653 interval cancers were diagnosed. Among the latter, 1,012 could be classified on the basis of findings in screening and diagnostic mammograms, consisting of 489 true interval cancers (48.2%), 235 false-negatives (23.2%), 172 minimal-signs (17.2%) and 114 occult tumors (11.3%). Information on the screening protocol and women's characteristics were obtained from the screening program registry. Cause-specific Cox regression models were used to estimate the hazard ratios (HR) of risks factors for interval cancer and incident screen-detected cancer. A multinomial regression model, using screen-detected tumors as a reference group, was used to assess the effect of breast density and other factors on the occurrence of interval cancer subtypes.

Results: A previous false-positive was the main risk factor for interval cancer (HR = 2.71, 95%CI: 2.28-3.23); this risk was higher for false-negatives (HR = 8.79, 95%CI: 6.24-12.40) than for true interval cancer (HR = 2.26, 95%CI: 1.59-3.21). A family history of breast cancer was associated with true intervals (HR = 2.11, 95%CI: 1.60-2.78), previous benign biopsy with a false-negatives (HR = 1.83, 95%CI: 1.23-2.71). High breast density was mainly associated with occult tumors (RRR = 4.92, 95%CI: 2.58-9.38), followed by true intervals (RRR = 1.67, 95%CI: 1.18-2.36) and false-negatives (RRR = 1.58, 95%CI: 1.00-2.49).

Conclusion: The role of women's characteristics differs among interval cancer subtypes. This information could be useful to improve effectiveness of breast cancer screening programmes and to better classify subgroups of women with different risks of developing cancer.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Flow chart of the study…
Figure 1. Flow chart of the study populations.
Figure 2. Cumulative hazard for interval cancer…
Figure 2. Cumulative hazard for interval cancer by the presence of a previous false-positive result, family history of breast cancer and previous benign biopsy outside screening.

References

    1. Independent UK Panel on Breast Cancer Screening (2012) The benefits and harms of breast cancer screening: an independent review. Lancet 380: 1778–1786.
    1. Njor S, Nyström L, Moss S, Paci E, Broeders M, et al. (2012) Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. J Med Screen 19 Suppl 1: 33–41.
    1. Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, et al... (2006) European Commission. European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis. 4th ed. Luxembourg: Office for Official Publications of the European Communities.
    1. Bulliard J-L, Sasieni P, Klabunde C, De Landtsheer J-P, Yankaskas BC, et al. (2006) Methodological issues in international comparison of interval breast cancers. Int J Cancer 119: 1158–1163.
    1. Bucchi L, Ravaioli A, Foca F, Colamartini A, Falcini F, et al. (2008) Incidence of interval breast cancers after 650,000 negative mammographies in 13 Italian health districts. J Med Screen 15: 30–35.
    1. Törnberg S, Kemetli L, Ascunce N, Hofvind S, Anttila A, et al. (2010) A pooled analysis of interval cancer rates in six European countries. Eur J Cancer Prev 19: 87–93.
    1. Heidinger O, Batzler WU, Krieg V, Weigel S, Biesheuvel C, et al. (2012) The incidence of interval cancers in the German mammography screening program: results from the population-based cancer registry in North Rhine-Westphalia. Dtsch Arztebl Int 109: 781–787.
    1. Payne JI, Caines JS, Gallant J, Foley TJ (2013) A review of interval breast cancers diagnosed among participants of the Nova Scotia Breast Screening Program. Radiology 266: 96–103.
    1. Lowery JT, Byers T, Hokanson JE, Kittelson J, Lewin J, et al. (2011) Complementary approaches to assessing risk factors for interval breast cancer. Cancer Causes Control 22: 23–31.
    1. Bennett RL, Sellars SJ, Moss SM (2011) Interval cancers in the NHS breast cancer screening programme in England, Wales and Northern Ireland. Br J Cancer 104: 571–577.
    1. Hofvind S, Yankaskas BC, Bulliard J-L, Klabunde CN, Fracheboud J (2009) Comparing interval breast cancer rates in Norway and North Carolina: results and challenges. J Med Screen 16: 131–139.
    1. Seigneurin A, Exbrayat C, Labarère J, Colonna M (2009) Comparison of interval breast cancer rates for two-versus single-view screening mammography: a population-based study. Breast 18: 284–288.
    1. Hofvind S, Vacek PM, Skelly J, Weaver DL, Geller BM (2008) Comparing screening mammography for early breast cancer detection in Vermont and Norway. J Natl Cancer Inst 100: 1082–1091.
    1. Domingo L, Sala M, Servitja S, Corominas JM, Ferrer F, et al. (2010) Phenotypic characterization and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona, Spain. Cancer Causes Control 21: 1155–1164.
    1. Domingo L, Salas D, Zubizarreta R, Baré M, Sarriugarte G, et al. (2014) Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain. Breast Cancer Res 16: R3.
    1. Kirsh VA, Chiarelli AM, Edwards SA, O'Malley FP, Shumak RS, et al. (2011) Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program. J Natl Cancer Inst 103: 942–950.
    1. Mandelson MT, Oestreicher N, Porter PL, White D, Finder CA, et al. (2000) Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 92: 1081–1087.
    1. Halapy E, Chiarelli AM, Klar N, Knight JA (2005) Accuracy of breast screening among women with and without a family history of breast and/or ovarian cancer. Breast Cancer Res Treat 90: 299–305.
    1. Pollán M, Ascunce N, Ederra M, Murillo A, Erdozáin N, et al. (2013) Mammographic density and risk of breast cancer according to tumor characteristics and mode of detection: a Spanish population-based case-control study. Breast Cancer Res 15: R9.
    1. Ascunce N, Salas D, Zubizarreta R, Almazán R, Ibáñez J, et al. (2010) Cancer screening in Spain. Ann Oncol 21 Suppl 3: iii43–51.
    1. Navarro C, Martos C, Ardanaz E, Galceran J, Izarzugaza I, et al. (2010) Population-based cancer registries in Spain and their role in cancer control. Ann Oncol 21 Suppl 3: iii3–13.
    1. Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, et al. (1995) Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 87: 670–675.
    1. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ (1998) Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 7: 1133–1144.
    1. Therneau TM, Grambsch PM (2000) Modeling Survival Data: Extending the Cox Model. Springer, New York.
    1. Pencina MJ, Larson MG, D'Agostino RB (2007) Choice of time scale and its effect on significance of predictors in longitudinal studies. Stat Med 26: 1343–1359.
    1. R Core Team (2014) R: A Language and Environment for Statistical Computing. Available: .
    1. Ashbeck EL, Rosenberg RD, Stauber PM, Key CR (2007) Benign breast biopsy diagnosis and subsequent risk of breast cancer. Cancer Epidemiol Biomarkers Prev 16: 467–472.
    1. Kabat GC, Jones JG, Olson N, Negassa A, Duggan C, et al. (2010) A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer. Cancer Causes Control 21: 821–828.
    1. Blanch J, Sala M, Román M, Ederra M, Salas D, et al. (2013) Cumulative risk of cancer detection in breast cancer screening by protocol strategy. Breast Cancer Res Treat 138: 869–877.
    1. Otten JDM, Fracheboud J, den Heeten GJ, Otto SJ, Holland R, et al. (2013) Likelihood of early detection of breast cancer in relation to false-positive risk in life-time mammographic screening: population-based cohort study. Ann Oncol 24: 2501–2506.
    1. Castells X, Román M, Romero A, Blanch J, Zubizarreta R, et al. (2013) Breast cancer detection risk in screening mammography after a false-positive result. Cancer Epidemiol 37: 85–90.
    1. Hoff SR, Abrahamsen A-L, Samset JH, Vigeland E, Klepp O, et al. (2012) Breast cancer: missed interval and screening-detected cancer at full-field digital mammography and screen-film mammography— results from a retrospective review. Radiology 264: 378–386.
    1. Hofvind S, Skaane P, Elmore JG, Sebuødegård S, Hoff SR, et al... (2014) Mammographic Performance in a Population-based Screening Program: Before, during, and after the Transition from Screen-Film to Full-Field Digital Mammography. Radiology: 131502.
    1. De Gelder R, Fracheboud J, Heijnsdijk EAM, den Heeten G, Verbeek ALM, et al. (2011) Digital mammography screening: weighing reduced mortality against increased overdiagnosis. Prev Med (Baltim) 53: 134–140.
    1. Domingo L, Romero A, Belvis F, Sánchez M, Ferrer J, et al. (2011) Differences in radiological patterns, tumour characteristics and diagnostic precision between digital mammography and screen-film mammography in four breast cancer screening programmes in Spain. Eur Radiol 21: 2020–2028.
    1. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, et al. (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81: 1879–1886.
    1. Hofvind S, Møller B, Thoresen S, Ursin G (2006) Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens. Int J Cancer 118: 3112–3117.
    1. Domingo L, Blanch J, Servitja S, Corominas JM, Murta-Nascimento C, et al. (2013) Aggressiveness features and outcomes of true interval cancers: comparison between screen-detected and symptom-detected cancers. Eur J Cancer Prev 22: 21–28.
    1. Guo YP, Martin LJ, Hanna W, Banerjee D, Miller N, et al. (2001) Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev 10: 243–248.
    1. Vilaprinyo E, Forné C, Carles M, Sala M, Pla R, et al. (2014) Cost-effectiveness and harm-benefit analyses of risk-based screening strategies for breast cancer. PLoS One 9: e86858.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel